Hero

Celyad publishes additional pre-clinical data in support of THINK trial

1

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

2

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad Announces First Quarter 2017 Business Update

3

Celyad Announces First Quarter 2017 Business Update

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

4

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

5

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

More info about Celyad

Latest News

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types

Discover all news

Carousel

Social Feed

Celyad publishes additional pre-clinical data in support of THINK trial. Read the Press Release: http://bit.ly/2tsbPTt

5 days ago

Celyad publishes additional pre-clinical data in support of THINK trial. Read the Press Release: http://bit.ly/2tsbPTt

Celyad publishes additional pre-clinical data in support of THINK trial Read the Press release:… https://t.co/mriSqt4j5w

5 days ago

Celyad publishes additional pre-clinical data in support of THINK trial Read the Press release:… https://t.co/mriSqt4j5w

Celyad reports promising early results at first dose level of the solid arm of the THINK trial… https://t.co/j3Gu1p0wZ7

1 week ago

Celyad reports promising early results at first dose level of the solid arm of the THINK trial… https://t.co/j3Gu1p0wZ7

Celyad reports promising early results at first dose level of the solid arm of the THINK trial http://bit.ly/2tDMvJo

1 week ago

Celyad reports promising early results at first dose level of the solid arm of the THINK trial http://bit.ly/2tDMvJo

Celyad publishes additional pre-clinical data in support of THINK trial Read the Press release:… https://t.co/mriSqt4j5w

5 days ago

Celyad publishes additional pre-clinical data in support of THINK trial Read the Press release:… https://t.co/mriSqt4j5w

Celyad reports promising early results at first dose level of the solid arm of the THINK trial… https://t.co/j3Gu1p0wZ7

1 week ago

Celyad reports promising early results at first dose level of the solid arm of the THINK trial… https://t.co/j3Gu1p0wZ7

Our poster on NKG2D CAR-T therapy dose escalation&expansion study targeting multiple solid/hemato tumor types @ASCO… https://t.co/ANzosqn3v8

2 weeks ago

Our poster on NKG2D CAR-T therapy dose escalation&expansion study targeting multiple solid/hemato tumor types @ASCO… https://t.co/ANzosqn3v8

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells https://t.co/GqE7V2ohlv

4 weeks ago

Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells https://t.co/GqE7V2ohlv

Celyad publishes additional pre-clinical data in support of THINK trial. Read the Press Release: http://bit.ly/2tsbPTt

5 days ago

Celyad publishes additional pre-clinical data in support of THINK trial. Read the Press Release: http://bit.ly/2tsbPTt

Celyad reports promising early results at first dose level of the solid arm of the THINK trial http://bit.ly/2tDMvJo

1 week ago

Celyad reports promising early results at first dose level of the solid arm of the THINK trial http://bit.ly/2tDMvJo

Celyad - Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

4 weeks ago

Celyad - Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells

Christian Homsy

1 month ago

Christian Homsy